FDA approved Dawnzera in US as first and only RNA-targeted prophylactic treatment for hereditary angioedema
Dawnzera demonstrated significant and sustained HAE attack rate reduction and long-term disease control
Dawnzera demonstrated significant and sustained HAE attack rate reduction and long-term disease control
AINU is set to accelerate its expansion footprint, enhance operational capabilities
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
Mistry is a seasoned finance professional having an extensive work experience spanning more than 25 years
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
Subscribe To Our Newsletter & Stay Updated